Why Biogen Stock Got Mashed on Monday
Healthcare company (NASDAQ: BIIB) wasn't looking very healthy on the stock market on Monday. Investors traded out of its shares after learning that the company plans to book a hefty charge in its first quarter, which will directly affect its bottom line. By the end of the day, Biogen's stock had lost nearly 3% of its value.
Before market open, Biogen divulged in a regulatory filing that it expects to record $34 million in pre-tax expenses in its first quarter of this year. These consist of in-process research and development costs, as well as upfront and milestone payments.
Image source: Getty Images.
Source Fool.com
Biogen Inc. Aktie
176,04 €
-2,06 %
Deutliches Buy-Überwiegen bei Biogen Inc. im Vergleich zu Sell-Einschätzungen.
Das Kursziel von 197 € für Biogen Inc. weist auf ein leicht positives Potenzial gegenüber dem aktuellen Kurs von 176.04 € hin.
